BiotechTube

Custirsen + Docetaxel

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer

Trial Timeline

Sep 1, 2012 → Jul 1, 2017

NCT ID
NCT01630733

About Custirsen + Docetaxel

Custirsen + Docetaxel is a phase 3 stage product being developed by Achieve Life Sciences for Non-Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01630733. Target conditions include Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01630733Phase 3UNKNOWN

Competing Products

20 competing products in Non-Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
pemetrexed + gemcitabineEli LillyPhase 2
52
ALIMTA + CarboplatinEli LillyPhase 2
52
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
44
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
77

Other Products from Achieve Life Sciences

Custirsen + Docetaxel + Prednisone + DexamethasonePhase 3
69
Cytisinicline + PlaceboPhase 3
69
Taxol + TOCOSOL PaclitaxelPhase 3
69
Cytisinicline + PlaceboPhase 3
69
custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisonePhase 3
69